Annai Systems has announced it will provide its STARPlatform next-generation sequencing data management solution to the Glioma Longitudinal AnalySiS (GLASS) consortium. The GLASS consortium consists of neuropathologists, clinicians, scientists, and bioinformaticians from leading institutions across the globe. Annai Systems’ STARPlatform will enable GLASS to manage whole exome and genome sequencing data across multiple research centers.
“We’re excited to announce that the GLASS consortium is adopting STARPlatform,” said Michael Penley, Annai Systems’ CEO. “We’re honored to partner with GLASS and provide our services to help them lead the charge in glioma tumor research. We developed our solutions to address the full range of needs for next-generation genomics research, from the individual researcher to large-scale consortia.”
GLASS aims to accelerate efforts to understand glioma tumor evolution and identify new ways to treat the tumors. The consortium was awarded a substantial grant by the National Brain Tumor Society earlier this year. The organizations spearheading the consortium include the University of Texas MD Anderson Cancer Center, University of California, San Francisco and the Samsung Medical Center.
“The GLASS consortium is focused on further understanding glioma tumors to help usher in more effective therapies to patients, and using the leading data technologies is a critical component of our daily operations,” said Roel Verhaak, Ph.D., GLASS’ lead investigator and assistant professor of bioinformatics and computational biology at the University of Texas MD Anderson Cancer Center. “STARPlatform provides a secure, collaborative workspace to normalize and share data, which is exceptionally important to us. Annai has one of the most innovative solutions in the industry that offers the functionality we need.”